Work

601 A First-in-human, Phase 1 Clinical Study of the Safety, Tolerability and Pharmacokinetics (PK) of G-202, a Thapsigargin-based PSMA-activated Prodrug, in Patients with Advanced Solid Tumors

Year: 2012

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(12)72398-5

Authors: D. Mahalingam, G. Wilding, S. Denmeade, J. Sarantopoulas, D. Cosgrove, J. Cetnar, N. Azad, J. Bruce, M. Kurman, M. Carducci

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2003286248

FWCI: 0.222

Cites:

Cited by: 1

Related to: 10